Edmund Huang

Edmund Huang

Auto-generated profile, based on publicly available information

Edmund Huang

Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
MNMaarten Naesens
Maarten Naesens
CRCandice Roufosse
Candice Roufosse
MHMark Haas
Mark Haas
CLCarmen Lefaucheur
Carmen Lefaucheur
RMRoslyn B. Mannon
Roslyn B. Mannon
MMMichael H Mengel
Michael H Mengel
The XVI-th Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from 19th-23rd September 2022, as a joint meeting with the Canadian Society of Transplantation. To mark the 30th anniversary of the first Banff Classification, pre-meeting discussions were held on the past, present, and future of the Banff Classification. This report is a summary of the meeting highlights that were most important in terms of their effect on the Classification, including discussions around microvascular inflammation and biopsy-based transcript analysis for diagnosis. In a post-meeting survey, agreement was reached on the delineation of the following phenotypes: (1) "Probable antibody-mediated rejection (AMR)", which represents DSA-positive cases with some histological features of AMR but below current thresholds for a definitive AMR diagnosis; and (2) "Microvascular inflammation (MVI), DSA-negative and C4d-negative", a phenotype of unclear cause requiring further study, which represents cases with MVI not explained by DSA. Although biopsy-based transcript diagnostics are considered promising and remain an integral part of the Banff Classification (limited to diagnosis of AMR), further work needs to be done to agree on the exact classifiers, thresholds, and clinical context of use.

2 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
OAOlivier Aubert
Olivier Aubert
CUCindy Ursule-Dufait
Cindy Ursule-Dufait
RBRomain Brousse
Romain Brousse
JGJuliette Gueguen
Juliette Gueguen
MRMaud Racapé
Maud Racapé
ALAlexandre Loupy
Alexandre Loupy
Donor-derived cell-free DNA (dd-cfDNA) is an emerging noninvasive biomarker that has the potential to detect allograft injury. The capacity of dd-cfDNA to detect kidney allograft rejection and its added clinical value beyond standard of care patient monitoring is unclear. We enrolled 2,882 kidney allograft recipients from 14 transplantation centers in Europe and the United States in an observational population-based study. The primary analysis included 1,134 patients. Donor-derived cell-free DNA levels strongly correlated with allograft rejection, including antibody-mediated rejection (P < 0.0001), T cell-mediated rejection (P < 0.0001) and mixed rejection (P < 0.0001). In multivariable analysis, circulating dd-cfDNA was significantly associated with allograft rejection (odds ratio 2.275; 95% confidence interval (CI) 1.902–2.739; P < 0.0001) independently of standard of care patient monitoring parameters. The inclusion of dd-cfDNA to a standard of care prediction model showed improved discrimination (area under the curve 0.777 (95% CI 0.741–0.811) to 0.821 (95% CI 0.784–0.852); P = 0.0011) and calibration. These results were confirmed in the external validation cohorts (n = 1,748) including a cohort of African American patients (n = 439). Finally, dd-cfDNA showed high predictive value to detect subclinical rejection in stable patients. Our study provides insights on the potential value of assessing dd-cfDNA, in addition to standard of care monitoring, to improve the detection of allograft rejection. ClinicalTrials.gov registration: NCT05995379.

6 February 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
EHEdmund Huang
Edmund Huang
SSSupreet Sethi
Supreet Sethi
APAlice Peng
Alice Peng
RNReiad Najjar
Reiad Najjar
JMJames Mirocha
James Mirocha
SJStanley C. Jordan
Stanley C. Jordan
Donor‐derived cell‐free DNA (dd‐cfDNA) became Medicare‐reimbursable in the United States in October, 2017 for the detection of rejection in kidney transplant recipients based on results from its pivotal validation trial, but has not yet been externally validated. We assessed 63 adult kidney transplant recipients with suspicion of rejection with dd‐cfDNA and allograft biopsy. Of these, 27 (43%) patients had donor‐specific antibodies and 34 (54%) were found to have rejection by biopsy. The percentage of dd‐cfDNA was higher among patients with antibody‐mediated rejection (ABMR; median 1.35%; interquartile range (IQR): 1.10%‐1.90%) compared to those with no rejection (median 0.38%, IQR: 0.26%‐1.10%; p<0.001) and cell‐mediated rejection (CMR; median: 0.27%, IQR: 0.19%‐1.30%; p=0.01). The dd‐cfDNA test did not discriminate patients with CMR from those without rejection. The area under the ROC curve (AUC) for CMR was 0.42 (95% CI: 0.17‐0.66). For ABMR, the AUC was 0.82 (95% CI: 0.71‐0.93) and a dd‐cfDNA ≥0.74% yielded a sensitivity of 100%, specificity 71.8%, PPV 68.6%, and NPV 100%. The dd‐cfDNA test did not discriminate CMR from no rejection among kidney transplant recipients, although performance characteristics were stronger for the discrimination of ABMR.

1 September 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
EHEdmund Huang
Edmund Huang
AMAngela Q. Maldonado
Angela Q. Maldonado
CKChristian Kjellman
Christian Kjellman
SJStanley C. Jordan
Stanley C. Jordan
The IgG-degrading enzyme derived from Streptococcus pyogenes (Imlifidase, Hansa Biopharma) is a novel agent that cleaves all four human subclasses of IgG and has therapeutic potential for HLA desensitization in kidney transplantation and antibody-mediated rejection. Data from clinical trials in kidney transplantation demonstrated rapid degradation of anti-HLA donor-specific antibodies facilitating HLA-incompatible transplantation, which led to conditional approval of imlifidase by the European Medicines Agency for desensitization in kidney transplant recipients of a deceased donor with a positive cross match. Important considerations arising from the early experiences with imilfidase on kinetics of donor-specific antibodies after administration, timing of complementary therapeutic monoclonal or polyclonal IgG antibodies, and interference with cross match assays should be recognized as imlifidase emerges as a therapeutic agent for clinical transplantation.

4 November 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
CRCandice Roufosse
Candice Roufosse
MNMaarten Naesens
Maarten Naesens
MHMark Haas
Mark Haas
CLCarmen Lefaucheur
Carmen Lefaucheur
RMRoslyn B. Mannon
Roslyn B. Mannon
MMMichael H Mengel
Michael H Mengel
The XVIth Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from September 19 to 23, 2022, as a joint meeting with the Canadian Society of Transplantation. In addition to a key focus on the impact of microvascular inflammation and biopsy-based transcript analysis on the Banff Classification, further sessions were devoted to other aspects of kidney transplant pathology, in particular T cell-mediated rejection, activity and chronicity indices, digital pathology, xenotransplantation, clinical trials, and surrogate endpoints. Although the output of these sessions has not led to any changes in the classification, the key role of Banff Working Groups in phrasing unanswered questions, and coordinating and disseminating results of investigations addressing these unanswered questions was emphasized. This paper summarizes the key Banff Meeting 2022 sessions not covered in the Banff Kidney Meeting 2022 Report paper and also provides an update on other Banff Working Group activities relevant to kidney allografts.

15 December 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AVAshley Phuong-Chi Anh Vo
Ashley Phuong-Chi Anh Vo
EHEdmund Huang
Edmund Huang
NANoriko Ammerman
Noriko Ammerman
MTMieko Toyoda
Mieko Toyoda
SGShili Ge
Shili Ge
SJStanley C. Jordan
Stanley C. Jordan
Alloantibodies are a significant barrier to successful transplantation. While desensitization has emerged, efficacy is limited. Interleukin-6 (IL-6) is an important mediator of inflammation and immune cell activation. Persistent IL-6 production increases risk for alloantibody production. Here we report our experience with clazakizumab (anti-IL-6) for desensitization of highly HLA-sensitized patients (HS). From March 2018 - September 2020, 20 HS patients were enrolled in an open label pilot study to assess safety and limited efficacy of clazakizumab desensitization. Patients received PLEX, IVIg, and clazakizumab 25mg monthly X6. If transplanted, graft function, pathology, HLA antibodies and regulatory immune cells were monitored. Transplanted patients received standard immunosuppression and clazakizumab 25mg monthly post-transplant. Clazakizumab was well tolerated and associated with significant reductions in class I and class II antibodies allowing 18 of 20 patients to receive transplants with no DSA rebound in most. Significant increases in Treg and Breg cells were seen post-transplant. Antibody-mediated rejection occurred in 3 patients. Mean estimated glomerular filtration rate at 12 months was 58±29ml/min/1.73m2. Clazakizumab was generally safe and associated with significant reductions in HLA alloantibodies and high transplant rates for highly-sensitized patients. However, confirmation of efficacy for desensitization requires assessment in randomized controlled trials.